Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty

Abstract From the Canadian patent

This invention is directed to pharmaceutical combination compositions and methods containing (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)- 5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-N-(2-(3a(R)-benzyl-2-methyl-3-oxo-2,3 3a, 4,6,7-hexahydro-, pyrazolo-4,3-cpyridin-5-yl)-1(R)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide or a pharmaceutically acceptable salt thereof methods of using such , compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty including osteoporosis, osteoporotic fracture low bone mass, frailty and low muscle mass.